Cyberonics to Participate in 2011 Credit Suisse Small and Mid Cap & Future of Energy Conference

HOUSTON, Sept. 13, 2011 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in epilepsy management, today announced it will participate in the 2011 Credit Suisse Small and Mid Cap & Future of Energy Conference on Tuesday, September 27, 2011, in New York.

Greg Browne, Cyberonics' Senior Vice President and Chief Financial Officer, will speak to the attendees of the conference at 10:40 AM Eastern Time.  This session will not be webcast.  Presentation materials can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on September 27, 2011.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Contact information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
[email protected]

SOURCE Cyberonics, Inc.

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.